Extended Gradients with Efficient Protein A Columns for the ProA-MS Analysis of mAb and msAb Variants

Importance of the Topic

Direct analysis and structural characterization of monoclonal and multispecific antibodies at early stages of biopharmaceutical development accelerates decision-making, ensures product quality, and supports regulatory compliance. Extended elution gradients coupled with high-efficiency Protein A affinity chromatography and high-resolution mass spectrometry (ProA-MS) enable identification of post-translational modifications and low-abundance variants directly from cell culture filtrates.

Objectives and Study Overview

This study evaluates the performance of a BioResolve Protein A MaxPeak Premier column under extended gradient elution for ProA-MS analysis of a standard monoclonal antibody (NISTmAb) and a mock multispecific antibody with engineered heavy-chain mutations. Key aims include intact variant identification, assessment of relative abundances, and evaluation of method linearity and recovery using ultraviolet absorbance at 280 nm (A280).

Methodology

Sample Preparation

• NISTmAb reference material (RM 8671) at 10 mg/mL.
• CHO clarified cell culture fluid (CCCF) containing ~0.035 mg/mL trastuzumab.
• Mock msAb (1 mg/mL) with two-point mutation (H338R, Y339F) to modulate Protein A affinity.

Chromatographic Conditions

• Column: BioResolve Protein A Affinity Column, 3.5 µm, 2.1×20 mm at ambient temperature.
• Mobile phases: 100 mM ammonium acetate for loading; 200 mM formic acid for elution.
• Flow rate: 0.20 mL/min; injection volume: 10 µL.
• Detection: UV absorbance at 280 nm for titer and variant quantitation.

Instrumentation Used

• UHPLC: ACQUITY UPLC with Binary Solvent Manager and Tunable UV detector.
• Mass spectrometer: Xevo G3 QTof, mass range 400–8000 m/z, scan time 1 s, source temp 120 °C, desolvation temp 500 °C.
• Software: UNIFI and waters_connect for data acquisition and analysis.

Main Results and Discussion

The extended gradient ProA-MS method resolved an oxidation variant of NISTmAb, characterized by a +16 Da mass shift and eluting before the main peak. This low-abundance species (1.2–1.4%) was detected both in neat and CCCF-diluted samples. A subtle shift in glycan distribution suggested a possible link between Fc glycosylation and methionine oxidation at the Protein A binding site.

For the mock msAb, three heavy-chain pairing variants (HCmHCm, HCnHCm, HCnHCn) were separated based on a 3.05 Da mass difference. Relative abundances measured by A280 were consistent across neat and CCCF-diluted samples, demonstrating method robustness.

Benefits and Practical Applications

• Direct ProA-MS analysis of clarified cell culture fluid reduces sample preparation time.
• Simultaneous UV and MS detection provides quantitative titer, variant relative abundance, and structural characterization.
• High-efficiency column with extended gradients enhances separation of low-abundance and closely related variants.

Future Trends and Potential Applications

Advances may include automation of ProA-MS workflows for high-throughput screening, integration with process analytical technology for real-time monitoring, and application to diverse Fc-based therapeutics. Combining alternative affinity ligands and multidimensional separations could further deepen insight into post-translational modifications and degradation pathways.

Conclusion

The study demonstrates that high-efficiency Protein A columns with extended gradient elution, coupled to high-resolution mass spectrometry, offer a powerful platform for rapid characterization of mAb and msAb variants directly from cell culture filtrates. The approach provides accurate variant identification, quantitation, and titer determination in a streamlined workflow.

References

1. Dunham WH, Mullin M, Gingras AC. Affinity-purification coupled to mass spectrometry: Basic principles and strategies. Proteomics. 2012;12(10):1576–1590.
2. Jakes C, et al. Rapid analysis of biotherapeutics using protein A chromatography coupled to orbitrap mass spectrometry. Anal Chem. 2021;93(40):13505–13512.
3. Cotham VC, et al. A generic platform to couple affinity chromatography with native mass spectrometry for the analysis of therapeutic monoclonal antibodies. J Pharm Biomed Anal. 2023;228:115337.
4. Gaza-Bulseco G, Faldu S, Hurkmans K, Chumsae C, Liu H. Effect of methionine oxidation of a recombinant monoclonal antibody on the binding affinity to protein A and protein G. J Chromatogr B. 2008;870(1):55–62.
5. Koza SM, Shiner S, Lauber MA. A Trap & Elute style 2D Protein A–SEC method for the analysis of monoclonal antibody titer and size variants in cell culture. Waters Application Note. 2025;720008902.
6. Koza SM, Muriithi B, Shiner S, Lauber MA. Direct-connect 2D Protein A–SEC method for mAb titer and size variants in cell culture. Waters Application Note. 2025;720008780.
7. Koza SM, Shiner S, Lauber MA. Lowering quantitation limits for mAb titer measurements using small-volume Protein A affinity columns. Waters Application Note. 2025;720008775.